Cellestial Health

Cellestial Health is a pre-clinical stage biotechnology company and University of Cambridge spinout developing small molecule therapeutics for Parkinson's disease and other neurodegenerative conditions.

The company's approach targets astrocytic networks, a class of brain cells whose dysregulation contributes to neuroinflammation and toxic protein aggregation in Parkinson's.

Its lead compounds are designed to stabilise astrocyte function and slow or halt disease progression, addressing an area of biology largely overlooked by existing therapeutic strategies.